BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grant CH, Gillis KA, Lees JS, Traynor JP, Mark PB, Stevens KI. Proton pump inhibitor use and progression to major adverse renal events: a competing risk analysis. QJM 2019;112:835-40. [PMID: 31251364 DOI: 10.1093/qjmed/hcz166] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Cholin L, Ashour T, Mehdi A, Taliercio JJ, Daou R, Arrigain S, Schold JD, Thomas G, Nally J, Nakhoul NL, Nakhoul GN. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression. BMC Nephrol 2021;22:264. [PMID: 34266395 DOI: 10.1186/s12882-021-02449-0] [Reference Citation Analysis]
2 Katzka DA, Kahrilas PJ. Advances in the diagnosis and management of gastroesophageal reflux disease. BMJ. [DOI: 10.1136/bmj.m3786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
3 Giusti S, Lin Y, Sogbetun F, Nakhoul N, Liu S, Shi L, Batuman V. The Effect of Proton Pump Inhibitor Use on the Course of Kidney Function in Patients with Chronic Kidney Disease Stages G3a to G4. Am J Med Sci 2021:S0002-9629(21)00187-7. [PMID: 34033809 DOI: 10.1016/j.amjms.2021.05.017] [Reference Citation Analysis]
4 Wu B, Li D, Xu T, Luo M, He Z, Li Y. Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system. Sci Rep 2021;11:3690. [PMID: 33574396 DOI: 10.1038/s41598-021-83099-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Broide E, Eindor-Abarbanel A, Shirin H, Richter V, Matalon S, Leshno M. Is administration of proton pump inhibitors in functional dyspepsia worth the risk of developing gastric cancer: a Markov model to bridge the gap between scientific evidence and clinical practice. BMJ Open 2020;10:e031091. [PMID: 32051298 DOI: 10.1136/bmjopen-2019-031091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Vengrus CS, Delfino VD, Bignardi PR. Proton pump inhibitors use and risk of chronic kidney disease and end-stage renal disease. Minerva Urol Nephrol 2021;73:462-70. [PMID: 33769018 DOI: 10.23736/S2724-6051.21.04116-3] [Reference Citation Analysis]